Using a lamellar structure as a delivery system, the
Sulidin® Nimesulide LPS gel provides enhanced
percutaneous penetration of Nimesulide and reduced
yellow staining on the skin. LPS Technology
worldwide patents are pending.
The
anti-inflammatory potency of nimesulide is similar
to or greater than indomethacin, diclofenac,
piroxicam and ibuprofen. Its analgesic activity is
similar to that of ibuprofen.
The Lamellar Penetration
System (LPS) is based on the concept that the
lamellar structure, which lies within the
interstitial spaces of the skin, has an affinity
to similar structures. Therefore, using a
lamellar structure as a delivery system
facilitates the penetration of soluble active
drug substances into the skin layers. The Embil
formulation delivers a soluble form of
nimesulide into the skin using this technology.
Additionally, the lamellar hydrophobic structure
protects against the direct staining of the
hydrophobic phase that contains the soluble
drug. Therapeutic indications: Sulidin®
nimesulide LPS Gel (Embil) is indicated for the
topical treatment of a variety of conditions
characterized by pain, inflammation and
stiffness, such as osteoarthritis, rheumatoid
arthritis, periarthritis, post traumatic or
acute musculoskeletal disorders including
tendonitis, tenosynovitis, bursitis, sprains,
strains and lower back pain, as well as sports
injuries. Sulidin® Nimesulide Lamellar
penetration System (LPS) gel contains 1% (w/w)
of nimesulide, a Cox-2 selective non steroidal
anti-inflammatory drug (NSAID) of the
sulfoanilide class. The anti-inflammatory
potency of nimesulide is similar to or greater
than that of indomethacin, diclofenac, piroxicam
and ibuprofen in animal models. Its analgesic
activity is similar to that of ibuprofen and
less than that of indomethacin in rats and mice.
Registred
PCT/IB99/01460 "Nimesulide containing topical pharmaceutical
compositions".
Approved Country and Number:
USA: 6,818,671; EP
Countries: 1105114; China: ZL99811909.1; Turkey: TR 2001 00455B;
Singapore: 2001 879-6; New Zealand: 510165; South Africa: 2001
1689; Eurasia*: 2001 00226; Australia: 756007; Czech Republic:
295601; Israel: 141365 *Eurasian Countries: Turkmenistan,
Azerbaijan, Moldova, Armenia, Bellarus, Russian Federation,
Kazakhstan, Kyrgyzstan, Tajikistan
|
Type of business relationship sought
|
Co-development for worldwide licensing. Outright
purchase of worldwide patent rights also possible
Dr Koral Embil
Vice President
Research and Development
|